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Influence of FK 506 on T Lymphocytes, Langerhans' Cells and the 
Expression of Cytokine Receptors and Adhesion Molecules in Psoriatic 
Skin Lesions: A Preliminary Study 
A.W. Thomson, M. Nalesnik, K. Abu-Elmagd, and T.E. Starzl 
PSORIASIS is a chronic dermatosis of presumed au-toimmune etiology 1 that is characterized by epider-
mal hyperproliferation and by infiltration of the dermis. 
epidennis. and stratum corneum by lymphocytes and other 
inftammatory cells. Activated CD4 + T cells and secreted 
cytokines. including IFN- (which is elevated in psoriatic 
lesions) and interleukin-2 ClL-2). have been implicated in 
disease pathogenesis. Thus. T cells are found in close 
association with MHC class II+ (HLA-DR+) epidermal 
Langerhans' cells (candidate antigen presenting cells).2 
Moreover. IFN- has been shown to induce the expression 
of HLA-DR and adhesion molecules (including intracellu-
lar adhesion molecule I; ICAM-!) on vascular endothe-
lium and epidermal keratinocytes.3 Increased expression 
of adhesion molecules on these cells promotes the binding 
of lymphocytes4 •s and may predispose both to the recruit-
ment ofT cells into lesional tissue and to their activation.6 
Cyclosporine A (CyA). an immunomodulatory drug 
used commonly to prevent graft rejection. inhibits CD4 + 
T-cell activation. cytokine gene expression. and cytokine 
production. It is highly effective in the treatment of psori-
asis.7 We have shown previously that CyA markedly 
reduces the T-cell infiltrate within lesional skin. including 
numbers of IL-2 receptor+ (lL-2R+) cells. This effect is 
evident within 4 weeks of the start of therapy.s However. 
we also observed the persistence of adhesion molecule 
expression on lesional vascular endothelium despite reso-
lution of the psoriatic plaques.9 FK 506 is a new immuno-
suppressive agent with a similar mode of action to Cy A. 10 
It has been shown to be highly effective in the prevention 
and treatment of organ transplant rejection and has been 
reported to exhibit fewer side effects than Cy A in trans-
plant patients. II . 12 Its efficacy in psoriasis has been dem-
onstrated recently in a preliminary study. 13 
In this study we examined immunohistochemical changes 
within lesional skin of patients with severe recalcitrant 
psoriasis before and following the instigation of systemic 
FK 506 therapy. In view of our aforementioned observa-
tions concerning Cy A. we were interested especially in the 
inftuence of FK 506 on T lymphocytes. epidermal Langer-
hans' cells. IL-2R-bearing lymphocytes. and the expres-
sion of adhesion molecules within lesional skin. 
MATERIALS AND METHODS 
Patients and Biopsies 
Elliptical or 3-mm punch biopsies were obtained under local 
xylocaine anesthesia from lesional skin of four female patients 
with severe chronic plaque psoriasis .. Tissue was obtained imme-
diately before and 4 weeks after start of treatment with 0.15 
mglkgld FK S06 (Fujisawa Pharmaceutical Co. Ltd.. Osaka. 
Japan) administered in oral gelatin capsules. Biopsies were 
mounted in OTC mounting medium (Fisher Scientific). snap-
frozen in arctonlliquid nitrogen. and then stored at - 70·C before 
sectioning. 
Immunohistochemistry 
The method described by Horrocks et al9 was used. Six-micron 
cryostat sections were fixed in acetone for 20 minutes. air-dried. 
then incubated for I hour at room temperature with the appropri· 
ate. primary. mouse anti-human monoclonal antibody. These 
included CDI (Langerhans' cells), cm (mature T cells), CD4lT 
helper cells: Langerhans' cells). and CDS (T suppressor/cytotoxic 
cells), CD2S (a chain IL-2R; activated T cells). CDw60 {disease· 
associated T cells),14 HLA-DR and the adhesion molecules 
Calla~/1U (f37. integrin family), CD54 (lCAM·\), ELAM (endo-
thelial leukocyte adhesion molecule), and VCAM (vascular cell 
adhesion molecule). Sections were incubated for 30 minutes with 
biotinylated polyclonal rabbit anti-mouse immunoglobulins 
(Dako). The color was developed using diaminobenzidine in 
buffered saline containing H20 2• 
RESULTS 
Clinical 
All patients showed marked improvement in their PASI 
(Psoriasis Area and Severity Index) score within 4 weeks 
of the start of FK 506 therapy. and histological examina-
tion of lesional skin revealed a rapid decrease in inflam-
matory cells and progressive loss of elongated rete pegs 
with the return of a normal stratum corneum. 
Immunophenotypic Analysis 
Examination of biopsies obtained during disease remission 
showed that, in comparison to pretreatment lesions. there 
were reductions in epidermal and dermal CD4 +, CD8+, 
CD25 + , and CDw60+ mononuclear cells (Fig l). In con-
trast. there was a striking rise in COl + epidermal Langer-
hans' cells. With respect to adhesion molecules, expres-
sion of CD54 (ICAM-I) on residual lymphocytes and 
vascular endothelium persisted during FK 506-induced 
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FK 506 ON PSORIATIC SKIN LESIONS 
Fig 1. Few residual IL·2R* (CD25+) mononuclear cells in the 
basal epidermis of lesional skin from a patient with severe psori-
asis showing marked reduction in disease activity 4 weeks after 
the start of systemic FK 506 therapy. (x 100) 
disease remission. although staining became more re-
stricted to the upper dermis. Staining for ELAM. which 
was observed in blood vessels throughout the dermis in 
active disease, was sitnilar or reduced in intensity in 
response to FK 506 treatment although there was disap-
pearance of positive cells in the deeper dermis (Fig 2). 
Blood vessel staining for VCAM was focal and only faintly 
positive in active disease specimens, and there was evi-
dence of persistent ~xpression during disease remission. 
DISCUSSION 
The findings of this preliminary immunohistochemical 
analysis of lesional skin from psoriasis patients treated 
with FK 506 are similar to those reported previously by 
several groups investigating the effects of systemic Cy A. 
Fig 2. Persistence of expression of the adhesion molecule ELAM 
on vascular endothelium within the dermis despite remission of 
psoriasis 4 weeks after the start of systemic FK 506 therapy. 
(X100) 
3331 
The reductions in overall T-cell numbers and in activated 
(lL-2R +) cells are consistent with the mode of action of 
FK 506. The significance of the increase in epidermal 
Langerhans' cells, which accompanied the diminution 
both in T-cell numbers and disease remission, remains to 
be elucidated. This early increase in Langerhans' cells 
upon instigation of therapy is not restricted to Cy A and FK 
506, as treatment of psoriasis with retinoids, PUV A, or 
anthralin has also been shown to elevate COl + cell num-
bers. IS Possible explanations have been discussed else-
where. 16 In vitro studies of the influence of these Langer-
hans' cells on lesional (CDw60+) T-cell function would 
prove informative. The persistence of CD54 and other 
adhesion molecule expression during FK 506-induced dis-
ease remission suggests the likelihood of facilitated T-cell 
extravasation and disease recurrence following drug cur-
tailment or withdrawal. as has been reported with Cy A and 
in two out of seven severe psoriasis patients treated thus 
far at the University of Pittsburgh Medical Center. Further 
in vitro studies are clearly required to further elucidate the 
in vivo action of FK 506 in psoriasis. 
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